GlaxoSmithKline (GSK) has appointed Deborah Waterhouse the chief executive officer (CEO) designate of ViiV Healthcare, a specialist human immunodeficiency virus (HIV) company established in November 2009 by GSK and Pfizer and later adding Shionogi as a partner in 2012, with the announcement that the current Viiv Healthcare CEO, Dr. Dominique Limet, will step down at the end of March 2017. Ms. Waterhouse, currently senior vice president (SVP) Primary Care, GSK US Pharmaceuticals, will take up the CEO designate role on January 1, 2017.

Ms. Waterhouse joined GSK in 1996, prior to which she led the US vaccines business. She has lived and worked in Europe, Asia, and the US and has a track record of performance in both specialty and primary care. She led the HIV business in the UK before heading the HIV Center of Excellence for Pharma Europe, and held international roles as general manager of Australia and New Zealand and SVP Central and Eastern Europe.

Dr. Limet steps down after seven years as CEO of ViiV Healthcare. Dr. Limet started his career as a general practitioner in France. He joined GSK in 1996 from Ciba Geigy, where he held various marketing and management positions. In 2000, Dr. Limet was appointed general manager of GSK France. He then became SVP, Southern & Eastern Europe area director and then head of GSK Personalized Medicine Strategy.

Cheryl MacDiarmid has been appointed to succeed Deborah as SVP Primary Care, GSK US Pharmaceuticals. Ms. MacDiarmid has served as vice president US Primary Care Sales since early 2015. She brings 20 years of experience in establishing key brands and building businesses in the US and Canada.

Source: GlaxoSmithKline